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ABSTRACT
Background: The concurrent presentation of non-Hodgkin lymphoma and multiple myeloma is a very rare condition and only few 
cases have been reported.
Case Presentation: In this case report, we discuss a patient who presented with abdominal pain, weight loss, and melena. 
After the patient’s admission, several examinations were conducted. Microscopic findings in pathological studies and 
immunohistochemistry staining studies revealed a malignant non-Hodgkin B-cell lymphoma. A monoclonal free light chain protein 
was documented in the urine protein electrophoresis. Serum protein electrophoresis was reported to be normal. Bone marrow 
biopsy demonstrated cellularity plasma cell aggregations as multiple myeloma. Small bowel segmental resection surgery was 
the treatment plan. To prevent the relapse of chemotherapy, rituximab in combination with cyclophosphamide, doxorubicin, 
vincristine, and prednisone chemotherapy was tolerated by the patient. Finally, melena did not last after the resection and 
hemoglobin returned to its normal range.
Conclusion: In conclusion, this case report suggests that both multiple myeloma and non-Hodgkin’s lymphoma are hematopoietic 
malignancies which originate from B-cell lymphocytes. To understand, properly manage, and treat this rare condition, multiple 
studies are required, and this can be achieved by comparing similar cases.
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Background
Multiple myeloma (MM) and non-Hodgkin’s lymphoma 
(NHL) are lymphoproliferative disorders. The simultane-
ous presentation of both MM and NHL is a rare association 
of lymphoproliferative disorders [1]. In this case report, 
a patient who presented with both disorders is discussed. 
Clinical presentations and features of MM and NHL are 
variable. The coexistence of MM and NHL can be defined 
with several different possible pathogenic mechanisms 
[2]. Pathological studies and immunohistochemistry 
staining studies were conducted to diagnose NHL B-cell 
lymphoma. Multiple myeloma was documented with 
bone marrow biopsy. In 1994, Geun Chan Lee et al. [2] 
described a patient presenting with petechiae, melena, and 
weight loss, which was later identified as coincidental 
MM and NHL.
Case Presentation
A 69-year-old man with a history of hypertension and 
Benign prostatic hyperplasia (BPH) presented with 
abdominal pain, weight loss, and melena during the last 
7 months. Abdominal pain was general and without radi-
ation. Nausea and vomiting during abdominal pain were 
reported. There was no fever, skin rash, lymphadenopa-
thy, and hepatosplenomegaly on examination. On exam-
ination, he appeared ill, pale, and cachectic. Complete 
blood count showed hemoglobin 8.6 g/dl, WBC 9.4 × 103/
µl, RBC 4.37 × 106/µl, Hematocrit (HCT) 29.5%, Mean 
corpuscular volume (MCV) 67.51 µl, Mean corpuscular 
hemoglobin (MCH) 19.68 pg, Mean corpuscular hemo-
globin concentration (MCHC) 29.15 g/dl, and Platelet 
(PLT) 183 × 103/µl. Other lab studies showed albumin 
4 g/dl, creatinine 1.2 mg/dl, Lactic Acid Dehydrogenase 
(LDH) 428U/l, Erythrocyte sedimentation rate (ESR) 40 
mm/hour, and Ca 9 mg/dl.
There was no significant endoscopic finding in esoph-
agogastroduodenoscopy. The colonoscopy report was nor-
mal too. Computed tomography scan (CT-scan) indicated 
a long, rigid, narrow loop with irregularities bound in the 
distal of the jejunum. The filling defect of the jejunum was 
compressive-induced because of the extreme increase in 
thickness. The CT scan findings suggested an infiltrative 
mass or lymphoma in the small intestine (Figure 1).
To conduct pathological studies, imaging-guided core 
needle biopsy was done. The specimen consisted of two 
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thread-like fragments of soft white tissues, totally measur-
ing about 20 × 0.1 cm. Microscopic studies demonstrated 
fragments of a neoplasm composed of large pleomorphic 
rather than discohesive cells. Immunohistochemistry stud-
ies showed the diffuse positive immunostaining of tumor 
cells by Leukocyte Common Antigen (LCA), CD20, 
PAX5, CD10, Bcl6, and Ki67(about 95%), scattered posi-
tive reaction with MUM1 and Bcl2, and negative staining 
with CD3, PanCK, and ALK1. According to these studies, 
a malignant non-Hodgkin B-cell-type lymphoma was diag-
nosed. Because of continuous complaints of melena, the 
patient was admitted for small bowel segmental resection. 
Another pathological study was conducted after resection. 
The specimen consisted of two portions of the small intes-
tine (M: 23 × 4 and 10 × 2 cm). The external surface of 
a large portion in the middle area of the meso showed a 
tumoral mass (M: 8 × 4 × 3 cm). One section of the tumor 
was in the submucosa with fish-flashy consistency and it 
had invaded the total intestinal wall. Microscopic findings 
in pathological studies suggested that the neoplastic tissue 
consisted of solid sheets of medium-sized lymphoid-like 
cells with vesicular nuclei, prominent nucleoli, and scanty 
eosinophilic to clear cytoplasm. Immunohistochemistry 
staining studies indicated negativity for Creatine kinase 
(CK) and vimentin and positivity for CD45 and CD20. 
CD3 was positive in some cells. The small bowel segmen-
tal resection was considered as the treatment plan for this 
patient. Rituximab in combination with cyclophospha-
mide, doxorubicin, vincristine, and prednisone (R-CHOP) 
chemotherapy was prescribed for six sessions for prevent-
ing the relapse of NHL [3].
 Bone marrow biopsy, bone marrow aspiration, and 
peripheral blood smear were conducted for NHL staging. 
Bone marrow aspiration smear revealed 1% myoblast 
and 35%–40% plasma cells. Myeloid maturation was 
shifted to the left and megakaryocytes were decreased 
(Figures 2–4). According to the classification system of 
NHL, the subtype of NHL in this case report was diffuse 
large B-cell lymphoma (DLBCL). Based on the staging 
system for NHL, which is known as the Lugano modi-
fication of the Ann Arbor staging system, this case was 
stage IE NHL. Bone marrow biopsy showed that 30% 
of cellularity consisted of trilineage hematopoietic cells. 
Figure 1. CT scan indicated a long, rigid, narrow loop with irregu-
larities bound to the distal of the jejunum.
Figure 2. BMA shows an increased number of plas-
ma cells (×100).
Figure 3. BMA shows an increased number of plasma 
cells (×1,000).
Figure 4. BMA shows double nucleotide plasma cells 
(×1,000).
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Many areas of the plasma cell sheets and aggregations 
were identified. According to these findings, a diagnosis 
of MM was made.
With regard to MM, according to these initial results, 
Sodium dodecyl sulfate page (SDS-PAGE) urine protein 
electrophoresis showed the presence of a monoclonal free 
light chain protein (12.3 mg/dl; Figure 5). Serum protein 
electrophoresis was normal. Although there was no clinical 
sign or symptom leading to MM and the patient did not 
mention any skeletal pain, a whole body bone scan was car-
ried out as a workup for MM and it reported to be normal.
Treatment was directed toward NHL because of intes-
tinal bleeding, which is a life-threatening condition. The 
patient tolerated the treatment well, melena was treated 
due to the surgical resection, and Hb was in the normal 
range.
Because the NHL in this case report is extranodal, the 
treatment response cannot be evaluated and monitored 
according to the Response Evaluation Criteria in Solid 
Tumors (RECIST) and Lugano criteria.
Discussion
The non-Hodgkin’s lymphoma is a major category and a 
diverse group of the lymphatic system’s tumors and neo-
plasms [1]. DLBCL is the subtype of NHL, diagnosed in 
this case, which is the most common histologic subtype of 
NHL [4]. The clinical presentations and features of stage 
I extranodal DLBCL can be variable due to the involved 
organs [5].
The principal characteristics of MM are neoplastic pro-
liferation of abnormal plasma cells in the bone marrow 
and the production of monoclonal immunoglobulin [6]. 
The clinical presentations of MM are a variable spectrum 
of features from asymptomatic to severely ill [7].
In this case report, the patient was diagnosed 
with NHL. Bone marrow biopsy and urine protein 
electrophoresis fulfilled criteria for MM. In the bone 
marrow biopsy, there were localized collections of 
plasma cells and 30% of cellularity consisted of triline-
age hematopoietic cells.
The simultaneous coexistence of both MM and NHL as 
a rare association of malignancies in the patient suggests 
specific studies about the possible translocations that can 
define the possible mechanism of this coexistence.
This case also offers additional support for studying 
more rare cases with regard to the association of lymph-
oproliferative and hematopoietic malignancies in order to 
compare the details of clinical presentations and features. 
Although these cases are rare, comparisons of similar 
cases can lead to opportunities for understanding proper 
clinical management and treatment.
Conclusion
In conclusion, this case suggests that both MM and NHL 
are hematopoietic malignancies which originate from 
B-cell lymphocytes. To understand, properly manage, and 
treat this rare condition multiple studies are required, and 
this can be achieved by comparing similar cases.
List of Abbreviations
DLBCL Diffuse large B-Cell lymphoma
MM Multiple myeloma
NHL Non-Hodgkin’s lymphoma
R-CHOP  Rituximab in combination with cyclophosphamide, 
doxorubicin, vincristine, and prednisone
Consent for publication
Written informed consent was obtained from the patient.
What is new?
The simultaneous presentation of non-Hodgkin’s lymphoma 
and multiple myeloma is a rare case.
Figure 5. SDS-PAGE urine protein electrophoresis showing the presence of a monoclonal free light chain protein.
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Summary of the case
1 Patient (gender, age) A 69-year-old man
2 Final diagnosis Non-Hodgkin lymphoma and multiple myeloma
3 Symptoms Weight loss and melena
4 Medications R-CHOP chemotherapy
5 Clinical procedure Six sessions of R-CHOP chemotherapy
6 Specialty Oncology
